Table 1.
Characteristics of the studies included in this meta-analysis
| Author year, country | sample | age | cancer stage | range of study duration | CG | Time point | Outcome variables | |
|---|---|---|---|---|---|---|---|---|
| Henderson 2012 [14] USA | 53/52 | 20–65 | N-II | Not reported | UC | 8week, 16week | FACT-B, CEC | |
| Hoffman 2012 [15] UK | 114/115 | 49.0 ± 9.26/50.1 ± 9.14 | N-III | 2005–2006 | Wait-listed control/UC | 8week,12wk | POMS, FACT-B | |
| Wurtzen 2013 [16] Denmark | 168/168 | 53.9 ± 10.1/54.4 ± 10.5 | I-III | Jun 2007-Jul 2009 | UC | 6mon, 12mo | SCL-90r, CES-D | |
| Lengacher 2014 [17] USA | 40/42 | 58.2 | N-III | Mar 2006 to Jul 2007 | UC | 6week | STAI, CES-D, SF-36, PSS, CARS | |
| Bower 2015 [18] USA | 39/32 | 46.1(28.4–60)/47.7(31.1–59.6) | N-III | Not reported | UC | baseline,6 and 12 wk. | PSS, CES-D, FSI, PSQI, BCPT, QLACS | |
| Lengacher 2016 [19] USA | 152/147 | 56.6 | N-III | Apr 2009-Mar2013 | UC | 6week,12 week | BPI, FSI, CES-D, STAI-S, CARS, SF-36 | |
| Kenne 2017 [20] Sweden | 62/52 | 57.2 ± 10.2 | early-stage breast cancer | Not reported | UC、Active control | 3mo | HADS, MSAS, SF-36, SoC, PTGI | |
| Zhang 2017 [21] China | 30/30 | 48.67 ± 8.49/46.00 ± 5.12 | I-III | 2014–2015 | UC | 8week, 3mon | PSS, STAI, PTGI | |
| Witek-Janusek 2019 [22] USA | 63/61 | 55.1 ± 9.8 | early-stage breast cancer | Not reported | ACC | 12week | PSS, CES-D, MFSI, PSQI | |
| Mirmahmoodi 2020 [23] Iran | 22/22 | 44.14 ± 11.19/45.62 ± 10.11 | Not reported | Aug2017 to Nov 2019 | UC | 8week |
BAI, PSS, BDI PSQI, BFI, HADS |
|
| Qixi Liu 2022 [24] China | 28/34 | Not reported | Not reported | July 2019 to January 2021. | UC, and combined group | 8week | PSQI, BFI, HADS | |
| Shergill 2022 [25] Canada | 31/39 | 51.3 ± 11.4/55.1 ± 9.6 | Patients with CNP | Jau2014-Nov2017 | UC | 8week, 3mon | PHQ-9, FFMQ, BPI | |
| Weimin Liu 2022 [26] China | 61/63 | 24.71 ± 3.69/23.69 ± 3.16 | I-II | July28,2021,to April 21,2022 | UC | 8week, 20week | HADS, RPFS-CV, BPI, FACT-B | |
| Wang 2023 [27] China | 106/105 | 48.97 ± 8.52/49.97 ± 7.88 | Not reported | Jan 2018 to Dec 2020 | UC | 8week | SAS, SDA, FACT-B | |
| Zhu 2023 [28] China | 50/51 | 47.96 ± 8.51/49.78 ± 7.48 | breast cancer under early chemotherapy. | February 2017 to June 2018 | UC | 8week | FACT-B, SAS, SDS, PTGI | |
FACT-B The breast cancer version functional Assessment of cancer therapy, CEC Courtauld Emotional Control Scale, POMS Profile of mood states, SCL-90r The Symptom Checklist-90-r, CES-D Center for Epidemiological studies Depression Scales, STAI State-Trait Anxiety Inventory, SF-36 Short-Form General Health Survey with 36 items, PSS Perceived Stress Scale, CARS Concerns about Recurrence Scale, FSI Fatigue Symptom Inventory, PSQI Pittsburgh Sleep Quality Index, BCPT Breast Cancer Prevention Trail Symptom Checklist, QLACS Quality of Life in Adult Cancer Survivors, BPI Brief Pain Inventory, HADS The Hospital Anxiety and Depression Scale, MSAS Memorial Symptom Assessment Scale, SoC Sense of Coherence, PTGI Posttraumatic Growth Inventory, MFSI Multidimensional Fatigue Scale Index, BAI Beck Anxiety Inventory, BDI Beck Depression Inventory, BFI Brief Fatigue Inventory, PHQ-9 The Neuropathic Pain Symptom Inventory, FFMQ Five Facet Mindfulness Questionnaire, RPFS-CV The Chinese version of the validated Piper fatigue assessment scale. SAS Self-rating Anxiety Scale, SDS Self-rating Depression Scale